Fred G. J. Tijl

513 total citations
20 papers, 370 citations indexed

About

Fred G. J. Tijl is a scholar working on Ophthalmology, Hematology and Hepatology. According to data from OpenAlex, Fred G. J. Tijl has authored 20 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Ophthalmology, 9 papers in Hematology and 8 papers in Hepatology. Recurrent topics in Fred G. J. Tijl's work include Ocular Oncology and Treatments (13 papers), Multiple Myeloma Research and Treatments (9 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). Fred G. J. Tijl is often cited by papers focused on Ocular Oncology and Treatments (13 papers), Multiple Myeloma Research and Treatments (9 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). Fred G. J. Tijl collaborates with scholars based in Netherlands, United States and Sweden. Fred G. J. Tijl's co-authors include Alexander L. Vahrmeijer, Peter J.K. Kuppen, Rob A.�E.�M. Tollenaar, Cornelis J.�H. van de Velde, Joost Rothbarth, Milan E. J. Pijl, H.H. Hartgrink, Henk H. Hartgrink, Mark C. Burgmans and Ellen Kapiteijn and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Fred G. J. Tijl

18 papers receiving 365 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fred G. J. Tijl Netherlands	13	223	153	125	101	60	20	370
Bita Hazhirkarzar United States	11	16 0.1×	141 0.9×	70 0.6×	9 0.1×	84 1.4×	27	341
Marc G. A. van Ijken Netherlands	9	15 0.1×	70 0.5×	120 1.0×	12 0.1×	67 1.1×	13	273
Pascal Génin France	10	18 0.1×	116 0.8×	194 1.6×	5 0.0×	91 1.5×	15	439
Diane Rushlow Canada	9	176 0.8×	5 0.0×	166 1.3×	11 0.1×	153 2.5×	11	496
Trinh Pham United States	7	151 0.7×	3 0.0×	307 2.5×	24 0.2×	132 2.2×	11	528
Bruno R. Bastos United States	10	42 0.2×	4 0.0×	130 1.0×	12 0.1×	89 1.5×	31	299
J. Denekamp United Kingdom	8	10 0.0×	17 0.1×	62 0.5×	19 0.2×	119 2.0×	12	277
Seppo Tuomaala Finland	6	423 1.9×	3 0.0×	314 2.5×	12 0.1×	73 1.2×	7	448
Maria Antonietta Blasi Italy	11	255 1.1×	2 0.0×	198 1.6×	12 0.1×	86 1.4×	33	426
Iman Zandieh Canada	6	11 0.0×	66 0.4×	239 1.9×	6 0.1×	140 2.3×	8	384

Countries citing papers authored by Fred G. J. Tijl

Since Specialization

Citations

This map shows the geographic impact of Fred G. J. Tijl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fred G. J. Tijl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fred G. J. Tijl more than expected).

Fields of papers citing papers by Fred G. J. Tijl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fred G. J. Tijl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fred G. J. Tijl. The network helps show where Fred G. J. Tijl may publish in the future.

Co-authorship network of co-authors of Fred G. J. Tijl

This figure shows the co-authorship network connecting the top 25 collaborators of Fred G. J. Tijl. A scholar is included among the top collaborators of Fred G. J. Tijl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fred G. J. Tijl. Fred G. J. Tijl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hoek, Lia van der, Frank M. Speetjens, Carla van Rijswijk, et al.. (2025). LBA59 Combined percutaneous hepatic perfusion with ipilimumab plus nivolumab in metastatic uveal melanoma (CHOPIN): A single-center, open-label, randomized, phase II study. Annals of Oncology. 36. S1602–S1602.

Fiocco, Marta, Frank M. Speetjens, Fred G. J. Tijl, et al.. (2024). Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases. CardioVascular and Interventional Radiology. 47(6). 741–750. 1 indexed citations

Burgmans, Mark C., Frank M. Speetjens, Arian R. van Erkel, et al.. (2023). Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial. CardioVascular and Interventional Radiology. 46(3). 350–359. 16 indexed citations

Geus‐Oei, Lioe‐Fee de, Arian R. van Erkel, R.W. van der Meer, et al.. (2022). Prospective evaluation of percutaneous hepatic perfusion with melphalan as a treatment for unresectable liver metastases from colorectal cancer. PLoS ONE. 17(1). e0261939–e0261939. 2 indexed citations

Burgmans, Mark C., Frank M. Speetjens, Arian R. van Erkel, et al.. (2022). Safety and efficacy of combined melphalan percutaneous hepatic perfusion (M-PHP) and ipilimumab plus nivolumab (IPI+NIVO) in metastasized uveal melanoma (mUM): First results of the phase Ib part of the CHOPIN trial.. Journal of Clinical Oncology. 40(16_suppl). 9560–9560.

Kooij, Monique K. van der, Frank M. Speetjens, Arian R. van Erkel, et al.. (2022). Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial. Trials. 23(1). 137–137. 15 indexed citations

Burgmans, Mark C., Lioe‐Fee de Geus‐Oei, Bas Boekestijn, et al.. (2020). Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study. Annals of Surgical Oncology. 28(2). 1130–1141. 22 indexed citations

Burgmans, Mark C., Marta Fiocco, Lioe‐Fee de Geus‐Oei, et al.. (2019). Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems’ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial. CardioVascular and Interventional Radiology. 42(6). 841–852. 24 indexed citations

Geus‐Oei, Lioe‐Fee de, Fred G. J. Tijl, Arian R. van Erkel, et al.. (2019). Embolization of variant hepatic arteries in patients undergoing percutaneous hepatic perfusion for unresectable liver metastases from ocular melanoma. Diagnostic and Interventional Radiology. 25(6). 451–458. 6 indexed citations

10.

Burgmans, Mark C., Fred G. J. Tijl, Jaap Vuyk, et al.. (2017). Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan. CardioVascular and Interventional Radiology. 40(8). 1196–1205. 18 indexed citations

11.

Burgmans, Mark C., Fred G. J. Tijl, Arian R. van Erkel, et al.. (2016). Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver. Journal of Visualized Experiments. 1 indexed citations

12.

13.

Burgmans, Mark C., Ellen Kapiteijn, Gré P.M. Luyten, et al.. (2016). Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres. Melanoma Research. 26(6). 588–594. 17 indexed citations

14.

Iersel, L.B.J. van, Emily Leede, Alexander L. Vahrmeijer, et al.. (2014). Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study. European Journal of Surgical Oncology. 40(11). 1557–1563. 13 indexed citations

15.

Iersel, L.B.J. van, Hans Gelderblom, Alexander L. Vahrmeijer, et al.. (2008). Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Annals of Oncology. 19(6). 1127–1134. 38 indexed citations

16.

Iersel, L.B.J. van, Hans Gelderblom, Alexander L. Vahrmeijer, et al.. (2008). Isolated Hepatic Perfusion with 200 mg Melphalan for Advanced Noncolorectal Liver Metastases. Annals of Surgical Oncology. 15(7). 1891–8. 38 indexed citations

17.

Iersel, L.B.J. van, Alexander L. Vahrmeijer, Fred G. J. Tijl, et al.. (2007). Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: A clinical and pharmacologic evaluation. European Journal of Surgical Oncology. 33(7). 874–881. 19 indexed citations

18.

Rothbarth, Joost, Milan E. J. Pijl, J. E. E. Keunen, et al.. (2004). Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Research. 14(1). 67–72. 62 indexed citations

19.

Rothbarth, Joost, Milan E. J. Pijl, Robert A.E.M. Tollenaar, et al.. (2003). An experimental minimally invasive perfusion technique for the treatment of liver metastases. European Journal of Surgical Oncology. 29(9). 757–763. 9 indexed citations

20.

Rothbarth, Joost, Milan E. J. Pijl, Alexander L. Vahrmeijer, et al.. (2003). Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. British journal of surgery. 90(11). 1391–1397. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact